WEKO3
インデックスリンク
アイテム
Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts
http://hdl.handle.net/2297/2783
http://hdl.handle.net/2297/27836233c38b-e463-4d05-bbf9-4274029fafac
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
ME-PR-KINUYA-S-1084.pdf (206.4 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2017-10-03 | |||||
| タイトル | ||||||
| タイトル | Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 著者 |
Kinuya, Seigo
× Kinuya, Seigo× Kawashima, Atsuhiro× Yokoyama, Kunihiko× Koshida, Kiyoshi× Konishi, Shota× Watanabe, Naoto× Shuke, Noriyuki× Bunko, Hisashi× Michigishi, Takatoshi× Tonami, Norihisa |
|||||
| 提供者所属 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 金沢大学大学院医学系研究科 | |||||
| 書誌情報 |
Journal of Nuclear Medicine 巻 43, 号 8, p. 1084-1089, 発行日 2002-08-01 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0161-5505 | |||||
| 出版者 | ||||||
| 出版者 | THE SOCIETY OF NUCLEAR MEDICINE INC | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Antiangiogenic therapy may prolong the dormancy of cancer lesions. Moreover, radioimmunotherapy (RIT) may eradicate this population of cells. This study dealt with determining the benefits associated with the combined usefulness of these 2 therapies with respect to inhibition of tumor growth. Methods: Antiangiogenic therapy using oral thalidomide (daily dose, 200 mg/kg) and RIT involving a single intravenous injection (4.63 MBq 131I-A7, an IgG1 murine monoclonal antibody) were conducted in mice bearing LS180 human colon cancer xenografts. RIT with an irrelevant IgG1, HPMS-1, was also performed as a control. Antiangiogenesis of thalidomide was investigated by immunohistochemical analysis of tumor sections. Results: Antiangiogenic therapy and RIT with 131I-A7 significantly suppressed the growth of xenografts. This combination produced more efficient tumor growth inhibition than did the monotherapy (P < 0.005). RIT using 131I-HPMS-1 was far less effective than 131I-A7, even when combined with thalidomide administration. Immunohistochemistry revealed a decrease in the microvessel number within tumors treated with thalidomide (P < 0.0001). Combined therapy further reduced the microvessel number (P < 0.01 vs. thalidomide monotherapy), Conclusion: The combination of RIT and thalidomide antiangiogenic therapy produces a better response of tumors than does monotherapy. Acting in concert, antiangiogenic therapy may prolong the dormancy of cancer lesions and RIT may eradicate this population of cells. | |||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
